Run-Du Pharmaceutical: The drug registration certificate of Olmesartan Medoxomil Amlodipine Tablets has been obtained.

Run Du shares announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for a drug named Amlodipine and Olmesartan Medoxomil tablets. The drug is used to treat primary hypertension, with the fixed dose combination suitable for adult patients whose blood pressure control is not adequate with either Amlodipine or Olmesartan alone. Each tablet of Amlodipine and Olmesartan Medoxomil contains 20mg of Olmesartan Medoxomil and 5mg of Amlodipine besylate. The approval of this drug registration certificate further enhances the company's product layout in the sartans category, which will help improve the company's competitiveness in the field of cardiovascular and cerebrovascular disease treatment, and will have a positive impact on future business performance.